Abstract
Pancreatic function tests were performed in 11 adult cystic fibrosis (CF) patients with a fecal fat excretion of more than 10% during treatment with pancrease 2 capsules three times a day. These tests included urinary p-aminobenzoic acid (PABA) excretion, fasting serum trypsin and pancreatic polypeptide (PP), and glucose and insulin in fasting and postprandial serum. Subsequently, the patients entered a double-blind placebo-controlled crossover study to assess the effect of gastric acid inhibition by 20 mg omeprazole on fecal fat excretion. Adjunct therapy with omeprazole resulted in a reduction of fecal fat excretion in patients with residual pancreatic function. This improvement showed significant positive correlations with urinary PABA excretion and the increase in serum PP after the meal (P<0.02 and P<0.05), but not with the other parameters studied. Therefore, the addition of omeprazole to pancrease is most successful in CF patients with residual pancreatic function, determined by urinary PABA excretion or incremental PP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zentler-Munro PL: Cystic fibrosis—a gastroenterological cornucopia. Gut 28:1531–1547, 1987
Oppenheimer E, Esterly J: Pathology of cystic fibrosis.In Perspectives in Pediatric Pathology, Vol 2. Chicago, Year Book Publishers 1975, pp 241–278
Andersen D: Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 56:344–399, 1938
Park RW, Grand RJ: Gastrointestinal manifestations of cystic fibrosis: a review. Gastroenterology 81:1143–1161, 1981
Stead RJ, Skypala I, Hodson ME, Batten JC: Enteric coated microspheres of pancreatin on the treatment of cystic fibrosis: Comparison with a standard enteric coated preparation. Thorax 42:533–537, 1987
Gow R, Francis P, Bradbear R, Shepherd R: Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an entericcoated preparation with and without antacids and cimetidine. Lancet 2:1071–1074, 1981
Bouquet J, Sinaasappel M, Neyens HJ: Malabsorption in cystic fibrosis: Mechanisms and treatment. J Pediatr Gastroenterol Nutr 7(suppl 1):S30-S35, 1988
Littlewood JM, Kelleher J, Walters MP, Johnson AW.In vivo andin vitro studies of microsphere pancreatic supplements. J Pediatr Gastroenterol Nutr 7(suppl 1):S22-S29, 1988
Zentler-Munro PL, Fitzpatrick WJF, Batten JC, Northfield TC: Effect of intrajejunal acidity on aqueous phase bile acid and lipid concentrations in pancreatic steatorrhoea due to cystic fibrosis. Gut 25:500–507, 1984
Heijerman HGM, Lamers CBHW, Dijkman JH, Bakker W: Ranitidine compared with the dimethylprostaglandin E2-analogue enprostil as adjunct to pancreatic enzyme replacement in adult cystic fibrosis. Scand J Gastroenterol 25(suppl 178): 26–31, 1990
Anonymous. Omeprazole. Lancet 2: 1187–1188, 1987
Walt RP, Gomes M, Wood EC, Logan LH, Pounder RE: Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 287:12–14, 1983
Lamers CBHW, Jansen JBMJ, Hafkenscheid JCM, Jongerius CM: Evaluation of exocrine and endocrine pancreatic function in older patients with cystic fibrosis. Pancreas 5(1):65–59, 1990
Lankisch PG: Exocrine pancreatic function tests. Gut 23:777–798, 1982
Koop H: Serum leyels of pancreatic enzymes and their clinical significance. Clin Gastroenterol 13:739–761, 1984
Stern A, Davidson GP, Kirubakaran CP, Deutsch J, Smith A, Hansky J: Pancreatic polypeptide secretion. A marker for disturbed pancreatic function in CF. Dig Dis Sci 28:870–873, 1983
Allen JM, Penketh ARL, Adrian TE, Lee YL, Sarson DL, Hodson ME, Batten JL, Bloom SR: Adult cystic fibrosis: Postprandial response of gut regulatory peptides. Gastroenterology 85:1379–1383, 1983
Hubbard VS, Wolf RO, Lester LA, Egge AC: Diagnostic and therapeutic applications of bentiromide screening test for exocrine pancreatic insufficiency in patients with cystic fibrosis. Dig Dis Sci 29:881–889, 1984
Hafkenscheid JCM, Hessels M, Jansen JBMJ, Lamers CBHW: Serum trypsin, α-amylase and lipase during bombesin stimulation in normal subjects and patients with pancreatic insufficiency. Clin Chim Acta 136:235–240, 1984
Lamers CBHW, Diemel CM, Jansen JBMJ: Comparative study of plasma pancreatic polypeptide responses to food, secretin and bombesin in normal subjects and in patients with chronic pancreatitis. Dig Dis Sci 29:102–108, 1984
Creutzfeldt W, Lamberts R, Brunner G: Serum gastrin concentrations and endocrine cell population during long-term treatment with omeprazole in man. Gut 25:A1341, 1984
Adrian TE, McKiernan J, Johnstone DI, Hiller EJ, Vyas H, Sarson DL, Bloom SR: Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 79:460–465, 1980
Van de Kamer JH, ten Bokkel Huinink H, Weyers HA: Rapid method for the determination of fat in faeces. J Biol Chem 177:347–355, 1949
Cox KL, Isenberg JW, Asher AB, Dooley RR: The effect of cimetidine on maldigestion in cystic fibrosis. J Pediatr 94:488–492, 1979
DiMagno EP: Controversies in the treatment of exocrine pancreatic insufficiency. Dig Dis Sci 27:485–490, 1982
Cox KL, Isenberg JN, Ament ME: Gastric hypersecretion in cystic fibrosis. J Pediatr Gastroenterol Nutr 1:559–565, 1982
Weizman ZVI, Forstner GG, Gaskin KJ, Kopelman H, Wong S, Durie PR: Bentiromide test for assessing pancreatic dysfunction using analysis of paraaminobenzoic acid in plasma and urine. Gastroenterology 89:596–604, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heijerman, H.G.M., Lamers, C.B.H.W., Bakker, W. et al. Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas. Digest Dis Sci 38, 1–6 (1993). https://doi.org/10.1007/BF01296765
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01296765